Stockscreener 앱 받기
85.86
20.13%
-21.64
시간 외 거래:
87.00
1.14
+1.33%
전일 마감가:
$107.50
열려 있는:
$106.05
하루 거래량:
3.10M
Relative Volume:
3.59
시가총액:
$9.28B
수익:
$769.10M
순이익/손실:
$46.67M
주가수익비율:
245.31
EPS:
0.35
순현금흐름:
$119.79M
1주 성능:
-22.06%
1개월 성능:
-23.98%
6개월 성능:
+90.46%
1년 성능:
+17.65%
1일 변동 폭
$84.13
$106.09
1주일 범위
$84.13
$118.42
52주 변동 폭
$28.66
$126.38
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
85.86 | 9.28B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-18 | 재개 | Truist | Buy |
| 2026-07-27 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2026-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2026-03-26 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
In a trial, 24% of patients with hard-to-control type 2 diabetes had excess cortisol. - Stock Titan
Corcept Therapeutics Incorporated Announces ADA/EASD Consensus Report Cites CATALYST Trial On Mifepristone For Hypercortisolism In Difficult-To-Control Type 2 Diabetes - www.marketscreener.com
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes - Yahoo Finance
Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics - Zacks Investment Research
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics - The Globe and Mail
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? - Zacks Investment Research
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? - Yahoo Finance
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics - Zacks Investment Research
Corcept Therapeutics Incorporat (CORT) Stock forecasts - Yahoo Finance Australia
Corcept Therapeutics director Wilson sells $1.15 million in shares - Investing.com
Corcept Therapeutics Director James N. Wilson Sells 10,000 Shares on October 15 Under 10b5-1 Plan - Kalkine Media
A director's trust sells 10,000 shares under a trading plan at Corcept Therapeutics (CORT). - Stock Titan
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains - Zacks Investment Research
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge - Zacks Investment Research
Corcept Therapeutics Incorporat (CORT) Stock forecasts - Yahoo Finance UK
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer - Zacks Investment Research
Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Zacks Investment Research
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance
Corcept Therapeutics (CORT) Stock Looks Fully Priced For Its Sales Story - Yahoo Finance
Corcept Therapeutics (CORT) Draws Options Attention, Is It Still 18% Below Fair Value? - Yahoo Finance
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo! Finance Canada
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Does Elevated Put Options Activity Change The Bull Case For Corcept Therapeutics Stock (CORT)? - Simply Wall Street
Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research
BMY Reports Mixed Phase III Trial Results, Stock Down - Zacks Investment Research
Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? - Zacks Investment Research
Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? - Yahoo Finance
Drugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case - Reuters
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
Corcept Therapeutics Inc (HTD.DU) Stock Forum & Discussion - Yahoo! Finance Canada
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS), DICK’S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR) - Supply Chain Digital
Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance
Corcept Therapeutics Insider Sold Shares Worth $2,906,601, According to a Recent SEC Filing - Yahoo Finance
Corcept Therapeutics (NasdaqCM:CORT) Stock Forecast & Analyst Predictions - Simply Wall Street
Corcept Therapeutics Insider Sold Shares Worth $1,160,731, According to a Recent SEC Filing - Yahoo Finance
Form 4 Corcept Therapeutics Incorporated For: 5 October By Investing.com - Investing.com India
Form 4 Corcept Therapeutics Incorporated For: 5 October By Investing.com - Investing.com Nigeria
Corcept Therapeutics president Sean Maduck sells $2.9 million in stock By Investing.com - Investing.com Australia
Corcept Therapeutics president Sean Maduck sells $2.9 million in stock - Investing.com
Corcept Therapeutics president sells $967k in shares - Investing.com
Corcept Therapeutics chief accounting officer sells $1.16m - Investing.com
Corcept Therapeutics Oncology President Reports Stock Option Exercise and Sales in Form 4 Filing - Kalkine Media
Corcept Therapeutics' Sean Maduck Executes Stock Option Exercises and Sells Shares Under 10b5-1 Plan - Kalkine Media
100,000 stock options awarded to Corcept (CORT) officer vest over four years, subject to continued service. - Stock Titan
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
코르셉트 테라퓨틱스 주식 (CORT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lyon Joseph Douglas | See Remarks |
Oct 02 '26 |
Option Exercise |
17.18 |
9,190 |
157,864 |
14,873 |
| Vieira Roberto Wandenkolk | President, Oncology |
Oct 02 '26 |
Option Exercise |
21.63 |
8,333 |
180,243 |
12,279 |
| Maduck Sean | See Remarks |
Oct 02 '26 |
Sale |
116.28 |
24,587 |
2,858,884 |
9,938 |
| Maduck Sean | See Remarks |
Oct 02 '26 |
Option Exercise |
8.27 |
24,587 |
203,334 |
34,525 |
| Lyon Joseph Douglas | See Remarks |
Oct 02 '26 |
Sale |
116.13 |
9,190 |
1,067,258 |
5,683 |
| Vieira Roberto Wandenkolk | President, Oncology |
Oct 02 '26 |
Sale |
116.10 |
8,333 |
967,448 |
3,946 |
| Lyon Joseph Douglas | See Remarks |
Oct 01 '26 |
Sale |
115.40 |
810 |
93,473 |
5,683 |
| Lyon Joseph Douglas | Officer |
Oct 01 '26 |
Proposed Sale |
115.23 |
10,000 |
1,152,300 |
0 |
| Maduck Sean | See Remarks |
Oct 01 '26 |
Sale |
115.54 |
413 |
47,717 |
9,938 |
| Lyon Joseph Douglas | See Remarks |
Oct 01 '26 |
Option Exercise |
13.56 |
810 |
10,984 |
6,493 |
2.70%
0.91%
자본화:
|
볼륨(24시간):